Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma

• Bosch FX , RibesJ, DiazM, CleriesR. Primary liver cancer: worldwide incidence and trends.Gastroenterology127(5), S5–S16 (2004).
   PubMed Web of Science ®Google Scholar
• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics.CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Altekruse SF , McGlynnKA, ReichmanME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J. Clin. Oncol.27(9), 1485–1491 (2009).
   PubMed Web of Science ®Google Scholar
• Yang L , ParkinDM, FerlayJ, LiLA, ChenYD. Estimates of cancer incidence in China for 2000 and projections for 2005.Cancer Epidemiol. Biomarkers Prev.14(1), 243–250 (2005).
   PubMed Web of Science ®Google Scholar
• Schafer DF , SorrellMF. Hepatocellular carcinoma.Lancet353(9160), 1253–1257 (1999).
   PubMed Web of Science ®Google Scholar
• Gomaa AI , KhanSA, ToledanoMB, WakedI, Taylor-RobinsonSD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.World J. Gastroenterol.14(27), 4300–4308 (2008).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM . Epidemiology and clinical presentation of hepatocellular carcinoma.J. Vasc. Interv. Radiol.13(9), S169–S171 (2002).
   PubMed Web of Science ®Google Scholar
• Block TM , MehtaAS, FimmelCJ, JordanR. Molecular viral oncology of hepatocellular carcinoma.Oncogene22(33), 5093–5107 (2003).
   PubMed Web of Science ®Google Scholar
• Perz JF , ArmstrongGL, FarringtonLA, HutinYJ, BellBP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J. Hepatol.45(4), 529–538 (2006).
   PubMed Web of Science ®Google Scholar
• De Mitri MS , CassiniR, MorsicaGet al. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma. J. Viral Hepat. 13(9), 574–581 (2006).
   PubMed Web of Science ®Google Scholar
• Benvegnu L , FattovichG, NoventaFet al. Concurrent hepatitis-B and hepatitis-C virus-infection and risk of hepatocellular-carcinoma in cirrhosis - a prospective-study. Cancer 74(9), 2442–2448 (1994).
   PubMed Web of Science ®Google Scholar
• Fargion S , FracanzaniAL, PipernoAet al. Prognostic factors for hepatocellular-carcinoma in genetic hemochromatosis. Hepatology 20(6), 1426–1431 (1994).
   PubMed Web of Science ®Google Scholar
• Caballeria L , ParesA, CastellsA, GinesA, BruC, RodesJ. Hepatocellular carcinoma in primary biliary cirrhosis. Similar incidence to that in hepatitis C virus-related cirrhosis.Am. J. Gastroenterol.96(4), 1160–1163 (2001).
   PubMed Web of Science ®Google Scholar
• Davila JA , MorganRO, ShaibY, McGlynnKA, El-SeragHB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study.Gastroenterology127(5), 1372–1380 (2004).
   PubMed Web of Science ®Google Scholar
• Yoo HY , PattCH, GeschwindJF, ThuluvathPJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the united states between 1987 and 2001: 5-year survival has improved significantly with time.J. Clin. Oncol.21(23), 4329–4335 (2003).
   PubMed Web of Science ®Google Scholar
• Vilana R , BruixJ, BruC, AyusoC, SoleM, RodesJ. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular-carcinoma.Hepatology16(2), 353–357 (1992).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RealMI, MontanaXet al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Lo CM , NganH, TsoWKet al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Cardenes HR , PriceTR, PerkinsSMet al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin. Transl Oncol. 12(3), 218–225 (2010).
   PubMed Web of Science ®Google Scholar
• Krishnan S , DawsonLA, SeongJet al. Radiotherapy for hepatocellular carcinoma: an overview. Ann. Surg. Oncol. 15(4), 1015–1024 (2008).
   PubMed Web of Science ®Google Scholar
• Gish RG , PortaC, LazarLet al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J. Clin. Oncol. 25(28), 4512–4512 (2007).
   Web of Science ®Google Scholar
• O’Dwyer PJ , GiantonioBJ, LevyDE, KauhJS, FitzgeraldDB, BensonAB. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the eastern cooperative oncology group’s study e1203.J. Clin. Oncol.24(18), 4143 (2006).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK , BelaniCP, SinghDAet al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A california consortium (CCC-p) trial. J. Clin. Oncol. 24(18), 4010 (2006).
   Web of Science ®Google Scholar
• Yeo W , MokTS, ZeeBet al. A randomized Phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97(20), 1532–1538 (2005).
   PubMedGoogle Scholar
• Endicott JA , LingV. The biochemistry of P-glycoprotein-mediated multidrug resistance.Ann. Rev. Biochem.58, 137–171 (1989).
   PubMed Web of Science ®Google Scholar
• Ng IOL , LiuCL, FanST, NgM. Expression of P-glycoprotein in hepatocellular carcinoma – a determinant of chemotherapy response.Am. J. Clin. Pathol.113(3), 355–363 (2000).
   PubMed Web of Science ®Google Scholar
• Park JG , LeeSK, HongIGet al. MDR1 gene-expression - its effect on drug-resistance to doxorubicin in human hepatocellular-carcinoma cell-lines. J. Natl Cancer Inst. 86(9), 700–705 (1994).
   PubMedGoogle Scholar
• Faried LS , FariedA, KanumaTet al. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of caski cells to paclitaxel. Eur. J. Cancer 42(7), 934–947 (2006).
   PubMed Web of Science ®Google Scholar
• VanderWeele DJ , ZhouRX, RudinCM. AKT up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.Mol. Cancer Ther.3(12), 1605–1613 (2004).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RicciS, MazzaferroVet al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng AL , KangYK, ChenZDet al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).
   PubMed Web of Science ®Google Scholar
• Aguilar F , HarrisCC, SunT, HollsteinM, CeruttiP. Geographic-variation of p53 mutational profile in nonmalignant human liver.Science264(5163), 1317–1319 (1994).
   PubMed Web of Science ®Google Scholar
• Hosono S , ChouMJ, LeeCS, ShihC. Infrequent mutation of p53 gene in hepatitis-B virus positive primary hepatocellular carcinomas.Oncogene8(2), 491–496 (1993).
   PubMed Web of Science ®Google Scholar
• Minouchi K , KanekoS, KobayashiK. Mutation of p53 gene in regenerative nodules in cirrhotic liver.J. Hepatol.37(2), 231–239 (2002).
   PubMed Web of Science ®Google Scholar
• Nose H , ImazekiF, OhtoM, OmataM. P53 gene-mutations and 17p allelic deletions in hepatocellular-carcinoma from Japan.Cancer72(2), 355–360 (1993).
   PubMed Web of Science ®Google Scholar
• Edamoto Y , HaraA, BiernatWet al. Alterations of rb1, p53 and wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 106(3), 334–341 (2003).
   PubMed Web of Science ®Google Scholar
• Ishizaki Y , IkedaS, FujimoriMet al. Immunohistochemical analysis and mutational analyses of β-catenin, axin family and APC genes in hepatocellular carcinomas. Int. J. Oncol. 24(5), 1077–1083 (2004).
   PubMed Web of Science ®Google Scholar
• Ito Y , TakedaT, SakonMet al. Expression and clinical significance of Erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 84(10), 1377–1383 (2001).
   PubMed Web of Science ®Google Scholar
• Santoni-Rugiu E , JensenMR, FactorVM, ThorgeirssonSS. Acceleration of c-Myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF)-α in transgenic mice is associated with TGF-β1 signaling disruption.Am. J. Pathol.154(6), 1693–1700 (1999).
   PubMed Web of Science ®Google Scholar
• Daveau M , ScotteM, FrancoisAet al. Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol. Carcinog. 36(3), 130–141 (2003).
   PubMed Web of Science ®Google Scholar
• Wang R , FerrellDL, FaouziS, MaherJJ, BishopJM. Activation of the met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.J. Cell Biol.153(5), 1023–1033 (2001).
   PubMed Web of Science ®Google Scholar
• Feitelson MA , SunB, TufanNLS, LiuJ, PanJB, LianZR. Genetic mechanisms of hepatocarcinogenesis.Oncogene21(16), 2593–2604 (2002).
   PubMed Web of Science ®Google Scholar
• Kubo T , YamamotoJ, ShikauchiY, NiwaY, MatsubaraK, YoshikawaH. Apoptotic speck protein-like, a highly homologous protein to apoptotic speck protein in the pyrin domain, is silenced by DNA methylation and induces apoptosis in human hepatocellular carcinoma.Cancer Res.64(15), 5172–5177 (2004).
   PubMed Web of Science ®Google Scholar
• Maeta Y , ShiotaG, OkanoJ, MurawakiY. Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells.Tumor Biol.26(6), 300–305 (2005).
   PubMedGoogle Scholar
• Matsuda Y , IchidaT, MatsuzawaJ, SugimuraK, AsakuraH. P16(ink4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.Gastroenterology116(2), 394–400 (1999).
   PubMed Web of Science ®Google Scholar
• Murata H , TsujiS, TsujiiMet al. Promoter hypermethylation silences cyclooxygenase-2 (COX-2) and regulates growth of human hepatocellular carcinoma cells. Lab. Invest. 84(8), 1050–1059 (2004).
   PubMed Web of Science ®Google Scholar
• Wong CM , LeeJMF, ChingYP, JinDY, NgIOL. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.Cancer Res.63(22), 7646–7651 (2003).
   PubMed Web of Science ®Google Scholar
• Wong IHN , LoYMD, ZhangJet al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59(1), 71–73 (1999).
   PubMed Web of Science ®Google Scholar
• Brechot C , PourcelC, LouiseA, RainB, TiollaisP. Presence of integrated hepatitis-B virus-DNA sequences in cellular DNA of human hepatocellular-carcinoma.Nature286(5772), 533–535 (1980).
   PubMed Web of Science ®Google Scholar
• Murakami Y , SaigoK, TakashimaHet al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54(8), 1162–1168 (2005).
   PubMed Web of Science ®Google Scholar
• Minami M , DaimonY, MoriKet al. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 24(27), 4340–4348 (2005).
   PubMed Web of Science ®Google Scholar
• Wang J , ChenivesseX, HengleinB, BrechotC. Hepatitis-B virus integration in a Cyclin-A gene in a hepatocellular-carcinoma.Nature343(6258), 555–557 (1990).
   PubMed Web of Science ®Google Scholar
• Feitelson MA , DuanLX. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma.Am. J. Pathol.150(4), 1141–1157 (1997).
   PubMed Web of Science ®Google Scholar
• Klein NP , SchneiderRJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras.Mol. Cell. Biol.17(11), 6427–6436 (1997).
   PubMed Web of Science ®Google Scholar
• Shih WL , KuoML, ChuangSE, ChengAL, DoongSL. Hepatitis B virus x protein inhibits transforming growth factor-β-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway.J. Biol. Chem.275(33), 25858–25864 (2000).
   PubMed Web of Science ®Google Scholar
• Balsano C , AvantaggiatiML, NatoliGet al. Full-length and truncated versions of the hepatitis-B virus (HBV) x-protein (px) transactivate the cMyc protooncogene at the transcriptional level. Biochem. Biophys. Res. Commun. 176(3), 985–992 (1991).
   PubMed Web of Science ®Google Scholar
• Twu JS , LaiMY, ChenDS, RobinsonWS. Activation of protooncogene c-jun by the x-protein of hepatitis-B virus.Virology192(1), 346–350 (1993).
   PubMed Web of Science ®Google Scholar
• Chirillo P , FalcoM, PuriPLet al. Hepatitis B virus px activates NF-kappa β-dependent transcription through a Raf-independent pathway. J. Virol. 70(1), 641–646 (1996).
   PubMed Web of Science ®Google Scholar
• Seto E , MitchellPJ, YenTSB. Transactivation by the hepatitis-B virus-x protein depends on AP-2 and other transcription factors.Nature344(6261), 72–74 (1990).
   PubMed Web of Science ®Google Scholar
• Lee JO , KwunHJ, JungJK, ChoiKH, MinDS, JangKL. Hepatitis B virus x protein represses E-cadherin expression via activation of DNA methyltransferase 1.Oncogene24(44), 6617–6625 (2005).
   PubMed Web of Science ®Google Scholar
• Arzumanyan A , FriedmanT, KoteiE, NgIO, LianZ, FeitelsonMA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer.Oncogene doi: 10.1038/onc.2011.255 (2011) (Epub ahead of print).
   Google Scholar
• Lee YH , YunYD. Hbx protein of hepatitis B virus activates JAK1–STAT signaling.J. Biol. Chem.273(39), 25510–25515 (1998).
   PubMed Web of Science ®Google Scholar
• Benn J , SchneiderRJ. Hepatitis-B virus HBx protein activates Ras-GTP complex-formation and establishes a Ras, Raf, MAP kinase signaling cascade.Proc. Natl Acad. Sci. USA91(22), 10350–10354 (1994).
   PubMed Web of Science ®Google Scholar
• Park US , ParkSK, LeeYI, ParkJG, LeeYI. Hepatitis B virus-x protein upregulates the expression of p21(waf1/cip1) and prolongs g1 -> s transition via a p53-independent pathway in human hepatoma cells.Oncogene19(30), 3384–3394 (2000).
   PubMed Web of Science ®Google Scholar
• Cha MY , KimCM, ParkYM, RyuWS. Hepatitis B virus x protein is essential for the activation of wnt/β-catenin signaling in hepatoma cells.Hepatology39(6), 1683–1693 (2004).
   PubMed Web of Science ®Google Scholar
• Lee YI , Kang-ParkS, DoSI, LeeYI. The hepatitis B virus-x protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade.J. Biol. Chem.276(20), 16969–16977 (2001).
   PubMed Web of Science ®Google Scholar
• Bader AG , KangSY, ZhaoL, VogtPK. Oncogenic PI3K deregulates transcription and translation.Nat. Rev. Cancer5(12), 921–929 (2005).
   PubMed Web of Science ®Google Scholar
• Engelman JA , LuoJ, CantleyLC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.Nat. Rev. Genet.7(8), 606–619 (2006).
   PubMed Web of Science ®Google Scholar
• Vivanco I , SawyersCL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer.Nat. Rev. Cancer2(7), 489–501 (2002).
   PubMed Web of Science ®Google Scholar
• Yap TA , GarrettMD, WaltonMI, RaynaudF, De BonoJS, WorkmanP. Targeting the PI3K–AKT–mTor pathway. Progress, pitfalls, and promises.Curr. Opin Pharmacol.8(4), 393–412 (2008).
   PubMed Web of Science ®Google Scholar
• Dunlop EA , TeeAR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms.Cell. Signal.21(6), 827–835 (2009).
   PubMed Web of Science ®Google Scholar
• Mamane Y , PetroulakisE, LebacquerO, SonenbergN. mTOR, translation initiation and cancer.Oncogene25(48), 6416–6422 (2006).
   PubMed Web of Science ®Google Scholar
• Freeburn RW , WrightKL, BurgessSJ, AstoulE, CantrellDA, WardSG. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.J. Immunol.169(10), 5441–5450 (2002).
   PubMed Web of Science ®Google Scholar
• Miao BC , SkidanI, YangJSet al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc. Natl Acad. Sci. USA 107(46), 20126–20131 (2010).
   PubMed Web of Science ®Google Scholar
• Ding L , GetzG, WheelerDAet al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Samuels Y , WangZH, BardelliAet al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554–554 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas RK , BakerAC, DebiasiRMet al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39(3), 347–351 (2007).
   PubMed Web of Science ®Google Scholar
• Wood LD , ParsonsDW, JonesSet al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Benistant C , ChapuisH, RocheS. A specific function for phosphatidylinositol 3-kinase α (p85 α-p110 α) in cell survival and for phosphatidylinositol 3-kinase β (p85 α-p110 β) in de novo DNA synthesis of human colon carcinoma cells.Oncogene19(44), 5083–5090 (2000).
   PubMed Web of Science ®Google Scholar
• Brugge J , HungMC, MillsGB. A new mutational AKTivation in the PI3K pathway.Cancer Cell12(2), 104–107 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y , TianZ, FuB, XinY. LOH on 10.23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions.Ann. Oncol.19, 43–43 (2008).
   Web of Science ®Google Scholar
• Cully M , YouH, LevineAJ, MakTW. Beyond PTEN mutations. The PI3K pathway as an integrator of multiple inputs during tumorigenesis.Nat. Rev. Cancer6(3), 184–192 (2006).
   PubMed Web of Science ®Google Scholar
• Feilotter HE , CoulonV, McVeighJLet al. Analysis of the 10.23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br. J. Cancer 79(5–6), 718–723 (1999).
   PubMed Web of Science ®Google Scholar
• Gray IC , StewartLMD, PhillipsSMAet al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 78(10), 1296–1300 (1998).
   PubMed Web of Science ®Google Scholar
• Bellacosa A , DefeoD, GodwinAKet al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64(4), 280–285 (1995).
   PubMed Web of Science ®Google Scholar
• Bleeker FE , FelicioniL, ButtittaFet al. AKT1(E17K) in human solid tumours. Oncogene 27(42), 5648–5650 (2008).
   PubMed Web of Science ®Google Scholar
• Malanga D , ScrimaM, De MarcoCet al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7(5), 665–669 (2008).
   PubMed Web of Science ®Google Scholar
• Sahin F , KannangaiR, AdegbolaO, WangJZ, SuG, TorbensonM. mTOR and P70S6 kinase expression in primary liver neoplasms.Clin. Cancer Res.10(24), 8421–8425 (2004).
   PubMed Web of Science ®Google Scholar
• Villanueva A , ChiangDY, NewellPet al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6), 1972–1983 (2008).
   PubMed Web of Science ®Google Scholar
• Sieghart W , FuerederT, SchmidKet al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83(4), 425–432 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou LD , HuangY, LiJD, WangZM. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.Med. Oncol.27(2), 255–261 (2010).
   PubMed Web of Science ®Google Scholar
• Tavian D , De PetroG, BenettiA, PortolaniN, GiuliniSM, BarlatiS. u-PA and c-Met mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.Int. J. Cancer87(5), 644–649 (2000).
   PubMed Web of Science ®Google Scholar
• Sakata H , TakayamaH, SharpR, RubinJS, MerlinoG, LarochelleWJ. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers.Cell Growth Differ.7(11), 1513–1523 (1996).
   PubMedGoogle Scholar
• Tovar V , AlsinetC, VillanuevaAet al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. Hepatol. 52(4), 550–559 (2010).
   PubMed Web of Science ®Google Scholar
• Mannova P , BerettaL. Activation of the N-Ras–PI3K–AKT–mTOR pathway by hepatitis C virus: control of cell survival and viral replication.J. Virol.79(14), 8742–8749 (2005).
   PubMed Web of Science ®Google Scholar
• Neef M , LedermannM, SaegesserH, SchneiderV, ReichenJ. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.J. Hepatol.45(6), 786–796 (2006).
   PubMed Web of Science ®Google Scholar
• Bader AG , KangSY, VogtPK. Cancer-specific mutations in PIK3CA are oncogenic in vivo.Proc. Natl Acad. Sci. USA103(5), 1475–1479 (2006).
   PubMed Web of Science ®Google Scholar
• Samuels Y , DiazLA, Schmidt-KittlerOet al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6), 561–573 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao JJ , LiuZN, WangL, ShinE, LodaMF, RobertsTM. The oncogenic properties of mutant p110 α and p110 β phosphatidylinositol 3-kinases in human mammary epithelial cells.Proc. Natl Acad. Sci. USA102(51), 18443–18448 (2005).
   PubMed Web of Science ®Google Scholar
• Lemke LE , Paine-MurrietaGD, TaylorCW, PowisG. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.Cancer Chemother. Pharmacol.44(6), 491–497 (1999).
   PubMed Web of Science ®Google Scholar
• Hu LM , ZaloudekC, MillsGB, GrayJ, JaffeRB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).Clin. Cancer Res.6(3), 880–886 (2000).
   PubMed Web of Science ®Google Scholar
• Amaravadi R , ThompsonCB. The survival kinases AKT and PIM as potential pharmacological targets.J. Clin. Invest.115(10), 2618–2624 (2005).
   PubMed Web of Science ®Google Scholar
• Knight ZA , GonzalezB, FeldmanMEet al. A pharmacological map of the PI3-K family defines a role for p110 α in insulin signaling. Cell 125(4), 733–747 (2006).
   PubMed Web of Science ®Google Scholar
• Marone R , CmijanovicV, GieseB, WymannMP. Targeting phosphoinositide 3-kinase - moving towards therapy.Iochim. Biophys. Acta1784(1), 159–185 (2008).
   PubMed Web of Science ®Google Scholar
• Fan QW , KnightZA, GoldenbergDDet al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5), 341–349 (2006).
   PubMed Web of Science ®Google Scholar
• Ladu S , CalvisiDF, ConnerEA, FarinaM, FactorVM, ThorgeirssonSS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/AKT/mTOR and COX-2 in a mouse model of human liver cancer.Gastroenterology135(4), 1322–1332 (2008).
   PubMed Web of Science ®Google Scholar
• Flinn IW , ByrdJC, FurmanRRet al. Preliminary evidence of clinical activity in a Phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J. Clin. Oncol. 27(15), 3543 (2009).
   Web of Science ®Google Scholar
• Jimeno A , HongDS, HeckerSet al. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. J. Clin. Oncol. 27(15), 3542 (2009).
   Google Scholar
• Wagner AJ , Von HoffDH, LorussoPMet al. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. 27(15), 3501 (2009).
   Web of Science ®Google Scholar
• Hilgard P , KlennerT, StekarJ, NossnerG, KutscherB, EngelJ. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.Eur. J. Cancer33(3), 442–446 (1997).
   PubMed Web of Science ®Google Scholar
• Van Ummersen L , BingerK, VolkmanJet al. A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 10(22), 7450–7456 (2004).
   PubMed Web of Science ®Google Scholar
• Campos LT , NemunaitisJ, StephensonJet al. Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J. Clin. Oncol. 27(15), e15505 (2009).
   Google Scholar
• Tolcher AW , YapTA, FearenIet al. A Phase I study of MK-2206, an oral potent allosteric AKT inhibitor (AKTi), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. 27(15), 3503 (2009).
   PubMedGoogle Scholar
• Chen KF , ChenHL, TaiWTet al. Activation of PI3K/AKT signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells J. Pharmacol. Exp. Ther. 337(1), 155–161 (2011).
   PubMed Web of Science ®Google Scholar
• Vezina C , KudelskiA, SehgalSN. Rapamycin (AY-22,989), a new antifungal antibiotic .1. Taxonomy of producing streptomycete and isolation of active principle.J. Antibiot. (Tokyo)28(10), 721–726 (1975).
   PubMed Web of Science ®Google Scholar
• Yatscoff RW , LegattDF, KnetemanNM. Therapeutic monitoring of rapamycin: a new immunosuppressive drug.Ther. Drug Monit.15(6), 478–482 (1993).
   PubMed Web of Science ®Google Scholar
• Faivre S , KroemerG, RaymondE. Current development of mTOR inhibitors as anticancer agents.Nat. Rev. Drug Discov.5(8), 671–688 (2006).
   PubMed Web of Science ®Google Scholar
• Guertin DA , SabatiniDM. Defining the role of mTOR in cancer.Cancer Cell12(1), 9–22 (2007).
   PubMed Web of Science ®Google Scholar
• Hay N . The AKT–mTOR tango and its relevance to cancer.Cancer Cell8(3), 179–183 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatini DM . mTOR and cancer: insights into a complex relationship.Nat. Rev. Cancer6(9), 729–734 (2006).
   PubMed Web of Science ®Google Scholar
• Atkins MB , HidalgoM, StadlerWMet al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Blaszkowsky LS , AbramsTA, MiksadRAet al. Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC). ASCO Annual Meeting, Chicago, IL, USA, 4–8 June (2010).
   Google Scholar
• Kelley RK , NimeiriHS, VergoMTet al. A Phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC). Gastrointestinal Cancer Symposium. San Francisco, CA, 20–22 January 2011.
   Google Scholar
• Campsen J , ZimmermanMA, MandellS, KaplanM, KamI. A decade of experience using mTOR inhibitors in liver transplantation.J. Transplant.2011, 913094 (2011).
   PubMedGoogle Scholar
• Levy G , SchmidliH, PunchJet al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results. Liver Transplant. 12(11), 1640–1648 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts RJ , WellsAC, UnittEet al. Sirolimus-induced pneumonitis following liver transplantation. Liver Transplant. 13(6), 853–856 (2007).
   PubMed Web of Science ®Google Scholar
• Montalbano M , NeffGW, YamashikiNet al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78(2), 264–268 (2004).
   PubMed Web of Science ®Google Scholar
• Toso C , MeebergGA, BigamDLet al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83(9), 1162–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Kneteman NM , OberholzerJ, Al SaghierMet al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplant. 10(10), 1301–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Schnitzbauer AA , ZuelkeC, GraebCet al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 10, 190 (2010).
   PubMed Web of Science ®Google Scholar
• Sarbassov DD , GuertinDA, AliSM, SabatiniDM. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex.Science307(5712), 1098–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Shah OJ , WangZY, HunterT. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.Curr. Biol.14(18), 1650–1656 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman ME , ApselB, UotilaAet al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7(2), 371–383 (2009).
   Web of Science ®Google Scholar
• Thoreen CC , KangSA, ChangJWet al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284(12), 8023–8032 (2009).
   PubMed Web of Science ®Google Scholar
• Chresta CM , DaviesBR, HicksonIet al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70(1), 288–298 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao JJ , ChengHL, JiaSDet al. The p110 α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl Acad. Sci. USA 103(44), 16296–16300 (2006).
   PubMed Web of Science ®Google Scholar
• Guillermet-Guibert J , BjorklofK, SalpekarAet al. The p110 β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 γ. Proc. Natl Acad. Sci. USA 105(24), 8292–8297 (2008).
   PubMed Web of Science ®Google Scholar
• O’Reilly KE , RojoF, SheQBet al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF , YoshimotoK, NghiemphuPet al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5(1), 139–151 (2008).
   Web of Science ®Google Scholar
• Maira SM , StaufferF, BrueggenJet al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7(7), 1851–1863 (2008).
   PubMed Web of Science ®Google Scholar
• Serra V , MarkmanB, ScaltritiMet al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68(19), 8022–8030 (2008).
   PubMed Web of Science ®Google Scholar
• Buchbinder EI , CohenMB, JungDEet al. In vitro efficacy of the dual PI3-Kinase/mTOR inhibitor NVP-BEZ235 in hepatocellular carcinoma. Molecular Cancer Therapeutics. 8(12 Suppl. 1), C60 (2009).
   Google Scholar
• Liu PX , ChengHL, RobertsTM, ZhaoJJ. Targeting the phosphoinositide 3-kinase pathway in cancer.Nat. Rev. Drug Discov.8(8), 627–644 (2009).
   PubMed Web of Science ®Google Scholar
• Ma WW , AdjeiAA. Novel agents on the horizon for cancer therapy.CA Cancer J. Clin.59(2), 111–137 (2009).
   PubMed Web of Science ®Google Scholar
• Chiorean EG , MahadevanD, HarrisWBet al. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J. Clin. Oncol. 27(15), 2558 (2009).
   Web of Science ®Google Scholar
• Moelling K , SchadK, BosseM, ZimmermannS, SchwenekerM. Regulation of Raf–AKT cross-talk.J. Biol. Chem.277(34), 31099–31106 (2002).
   PubMed Web of Science ®Google Scholar
• Carracedo A , MaL, Teruya-FeldsteinJet al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118(9), 3065–3074 (2008).
   PubMed Web of Science ®Google Scholar
• Raynaud FI , EcclesS, ClarkePAet al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67(12), 5840–5850 (2007).
   PubMed Web of Science ®Google Scholar
• Beuvink I , BoulayA, FumagalliSet al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6), 747–759 (2005).
   PubMed Web of Science ®Google Scholar
• Mondesire WH , JianWG, ZhangHXet al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10(20), 7031–7042 (2004).
   PubMed Web of Science ®Google Scholar
• Wu LC , BirleDC, TannockIF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.Cancer Res.65(7), 2825–2831 (2005).
   PubMed Web of Science ®Google Scholar
• Yan HJ , FrostP, ShiYJet al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 66(4), 2305–2313 (2006).
   PubMed Web of Science ®Google Scholar
• Tam KH , YangZF, LauCK, LamCT, PangRWC, PoonRTP. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma.Cancer Lett.273(2), 201–209 (2009).
   PubMed Web of Science ®Google Scholar
• Piguet AC , SemelaD, KeoghAet al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J. Hepatol. 49(1), 78–87 (2008).
   PubMed Web of Science ®Google Scholar
• Bu XX , LeC, JiaFQet al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol. Ther. 7(3), 392–396 (2008).
   PubMed Web of Science ®Google Scholar
• Patil MA , ChuaMS, PanKHet al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24(23), 3737–3747 (2005).
   PubMed Web of Science ®Google Scholar
• Tung CY , JenCH, HsuMT, WangHW, LinCH. A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets.BMC Genomics10, (2009).
   PubMed Web of Science ®Google Scholar
• Nowak AK , ChowPKH, FindlayM. Systemic therapy for advanced hepatocellular carcinoma: a review.Eur. J. Cancer40(10), 1474–1484 (2004).
   PubMed Web of Science ®Google Scholar
• Nies AT , KonigJ, PfannschmidtM, KlarE, HofmannWJ, KepplerD. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma.Int. J. Cancer94(4), 492–499 (2001).
   PubMed Web of Science ®Google Scholar
• Chao Y , ChanWK, BirkhoferMJet al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br. J. Cancer 78(1), 34–39 (1998).
   PubMed Web of Science ®Google Scholar
• Hebbar M , ErnstO, CattanSet al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 70(2), 154–158 (2006).
   PubMed Web of Science ®Google Scholar
• Szebeni J , AlvingCR, SavaySet al. Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions. Int. Immunopharmacol. 1(4), 721–735 (2001).
   PubMed Web of Science ®Google Scholar
• Gelderblom H , VerweijJ, NooterK, SparreboomA. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation.Eur. J. Cancer37(13), 1590–1598 (2001).
   PubMed Web of Science ®Google Scholar
• Green MR , ManikhasGM, OrlovSet al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17(8), 1263–1268 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou Q , ChingAK, LeungWKet al. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Int. J. Oncol. 38(3), 721–731 (2011).
   PubMed Web of Science ®Google Scholar
• Blum JL , SavinMA, EdelmanGet al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 7(11), 850–856 (2007).
   PubMed Web of Science ®Google Scholar
• Marimpietri D , BrignoleC, NicoBet al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin. Cancer Res. 13(13), 3977–3988 (2007).
   PubMed Web of Science ®Google Scholar
• Campostrini N , MarimpietriD, TotoloAet al. Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. Proteomics 6(15), 4420–4431 (2006).
   PubMed Web of Science ®Google Scholar
• Shafer A , ZhouCX, GehrigPA, BoggessJF, Bae-JumpVL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.Int. J. Cancer126(5), 1144–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Haritunians T , MoriA, O’KellyJ, LuongQT, GilesFJ, KoefflerHP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.Leukemia21(2), 333–339 (2007).
   PubMed Web of Science ®Google Scholar
• Sessa C , TosiD, ViganoLet al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann. Oncol. 21(6), 1315–1322 (2010).
   PubMed Web of Science ®Google Scholar
• Ribatti D , NicoB, MangieriDet al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol. Histopathol. 22(3), 285–289 (2007).
   PubMed Web of Science ®Google Scholar
• Yu K , Toral-BarzaL, ShiC, ZhangWG, ZaskA. Response and determinants of cancer cell susceptibility to PI3K inhibitors.Cancer Biol. Ther.7(2), 307–315 (2008).
   PubMed Web of Science ®Google Scholar
• Ito Y , SasakiY, HarimotoMet al. Activation of mitogen-activated protein kinase extracellular signal-regulated protein kinase in human hepatocellular carcinoma. Hepatology 26(4), 1002–1002 (1997).
   Web of Science ®Google Scholar
• Schmidt CM , MckillopIH, CahillPA, SitzmannJV. Increased MAPK expression and activity in primary human hepatocellular carcinoma.Biochem. Biophys. Res. Commun.236(1), 54–58 (1997).
   PubMed Web of Science ®Google Scholar
• Saini KS , Piccart-GebhartMJ. Dual targeting of the PI3K and MAPK pathways in breast cancer.Asia-Pacific Journal of Oncology & Hematology2(2), 13–17(2010).
   Google Scholar
• Kinkade CW , Castillo-MartinM, Puzio-KuterAet al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118(9), 3051–3064 (2008).
   PubMed Web of Science ®Google Scholar
• Lasithiotakis KG , SinnbergTW, SchittekBet al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128(8), 2013–2023 (2008).
   PubMed Web of Science ®Google Scholar
• Liu L , CaoYC, ChenCet al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851–11858 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Z , ZhouJ, FanJet al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 14(16), 5124–5130 (2008).
   PubMed Web of Science ®Google Scholar
• Shinohara ET , CaoC, NiermannKet al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24(35), 5414–5422 (2005).
   PubMed Web of Science ®Google Scholar
• Albert JM , KimKW, CaoC, LuB. Targeting the AKT/mammalian target of rapamycin pathway for radiosensitization of breast cancer.Mol. Cancer Ther.5(5), 1183–1189 (2006).
   PubMed Web of Science ®Google Scholar
• Manegold PC , ParingerC, KulkaUet al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer. Clin. Cancer Res. 14(3), 892–900 (2008).
   PubMed Web of Science ®Google Scholar
• Pang RWC , PoonRTP. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.Oncology72, 30–44 (2007).
   PubMed Web of Science ®Google Scholar
• Llovet JM , BruixJ. Molecular targeted therapies in hepatocellular carcinoma.Hepatology48(4), 1312–1327 (2008).
   PubMed Web of Science ®Google Scholar
• Tanaka S , AriiS. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategiesJ. Gastroenterol.46(3), 289–296 (2011).
   PubMed Web of Science ®Google Scholar
• Buontempo F , ErsahinT, MissiroliSet al. Inhibition of AKT signaling in hepatoma cells induces apoptotic cell death independent of AKT activation status. Invest. New Drugs (2010) (Epub ahead of print).
   Google Scholar
• Schoniger-Hekele M , MullerC. Pilot study: rapamycin in advanced hepatocellular carcinoma.Aliment. Pharmacol. Ther.32(6), 763–768 (2010).
   PubMed Web of Science ®Google Scholar
• Na GC , TimasheffSN. Thermodynamic linkage between tubulin self-association and the binding of vinblastine.Biochemistry19(7), 1355–1365 (1980).
   PubMed Web of Science ®Google Scholar
• Plosker GL , FiggittDP. Rituximab: a review of its use in non-hodgkin’s lymphoma and chronic lymphocytic leukaemia.Drugs63(8), 803–843 (2003).
   PubMed Web of Science ®Google Scholar
• Sandler AB . Chemotherapy for small cell lung cancer.Semin. Oncol.30(1), 9–25 (2003).
   PubMed Web of Science ®Google Scholar
• Jassem J , KosmidisP, RamlauRet al. Oral vinorelbine in combination with cisplatin. A novel active regimen in advanced non-small-cell lung cancer. Ann. Oncol. 14(11), 1634–1639 (2003).
   PubMed Web of Science ®Google Scholar
• Seidman AD . Monotherapy options in the management of metastatic breast cancer.Semin. Oncol.30(2), 6–10 (2003).
   PubMed Web of Science ®Google Scholar
• Okouneva T , HillBT, WilsonL, JordanMA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics.Mol. Cancer Ther.2(5), 427–436 (2003).
   PubMed Web of Science ®Google Scholar
• Panda D , AnanthnarayanV, LarsonG, ShihC, JordanMA, WilsonL. Interaction of the antitumor compound cryptophycin-52 with tubulin.Biochemistry39(46), 14121–14127 (2000).
   PubMed Web of Science ®Google Scholar
• Towle MJ , SalvatoKA, BudrowJet al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogs of halichondrin B. Cancer Res. 61(3), 1013–1021 (2001).
   PubMed Web of Science ®Google Scholar
• Loganzo F , DiscafaniCM, AnnableTet al. HTI-286, a synthetic analog of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63(8), 1838–1845 (2003).
   PubMed Web of Science ®Google Scholar
• Hamel E . Natural-products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin a, dolastatin 10 and dolastatin 15 and halichondrin B.Pharmacol. Ther.55(1), 31–51 (1992).
   PubMed Web of Science ®Google Scholar
• Manfredi JJ , ParnessJ, HorwitzSB. Taxol binds to cellular microtubules.J. Cell Biol.94(3), 688–696 (1982).
   PubMed Web of Science ®Google Scholar
• Belani CP , LangerC. First-line chemotherapy for NSCLC: an overview of relevant trials.Lung Cancer38, S13–S19 (2002).
   PubMed Web of Science ®Google Scholar
• Bollag DM , McQueneyPA, ZhuJet al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11), 2325–2333 (1995).
   PubMed Web of Science ®Google Scholar
• Honore S , KamathK, BraguerD, WilsonL, BriandC, JordanMA. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation.Mol. Cancer Ther.2(12), 1303–1311 (2003).
   PubMed Web of Science ®Google Scholar
• Skoufias DA , WilsonL. Mechanism of inhibition of microtubule polymerization by colchicines: inhibitory potencies of unliganded colchicine and tubulin colchicine complexes.Biochemistry31(3), 738–746 (1992).
   PubMed Web of Science ®Google Scholar
• Tozer GM , KanthouC, ParkinsCS, HillSA. The biology of the combretastatins as tumour vascular targeting agents.Int. J. Experimental Pathology83(1), 21–38 (2002).
   PubMed Web of Science ®Google Scholar
• Lakhani NJ , SarkarMA, VenitzJ, FiggWD. 2-methoxyestradiol, a promising anticancer agent.Pharmacotherapy23(2), 165–172 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshimatsu K , YamaguchiA, YoshinoH, KoyanagiN, KitohK. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.Cancer Res.57(15), 3208–3213 (1997).
   PubMed Web of Science ®Google Scholar
• Panda D , MillerHP, IslamK, WilsonL. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.Proc. Natl Acad. Sci. USA94(20), 10560–10564 (1997).
   PubMed Web of Science ®Google Scholar
• Jordan MA , WilsonL. Microtubules as a target for anticancer drugs.Nat. Rev. Cancer4(4), 253–265 (2004).
   PubMed Web of Science ®Google Scholar
• Martelli AM , ChiariniF, EvangelistiCet al. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol. Histopathol. 25(5), 669–680 (2010).
   PubMed Web of Science ®Google Scholar

Websites

• Sanger Institute website www.sanger.ac.uk/genetics/CGP/cosmic
   Google Scholar
• NCI Clinical Trial website www.clinicaltrials.gov
   Google Scholar
• Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer http://clinicaltrials.gov/ct2/show/NCT01005199
   Google Scholar
• Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma http://clinicaltrials.gov/ct2/show/NCT01008917
   Google Scholar
• Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) http://clinicaltrials.gov/ct2/show/NCT01335074
   Google Scholar
• MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy http://clinicaltrials.gov/ct2/show/NCT01239355
   Google Scholar
• Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery http://clinicaltrials.gov/ct2/show/NCT00467194
   Google Scholar
• Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) http://clinicaltrials.gov/ct2/show/NCT00390195
   Google Scholar
• RAD001 in Advanced Hepatocellular Carcinoma http://clinicaltrials.gov/ct2/show/NCT00516165
   Google Scholar
• Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer http://clinicaltrials.gov/ct2/show/NCT01009801
   Google Scholar
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma http://clinicaltrials.gov/ct2/show/NCT01035229
   Google Scholar
• Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor http://clinicaltrials.gov/ct2/show/NCT01010126
   Google Scholar
• Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis Trial: NCT01079767 http://linkedct.org/resource/trial/nct01079767/
   Google Scholar
• Hepatocellular Carcinoma (HCC)_Torisel_ http://clinicaltrials.gov/ct2/show/NCT01251458
   Google Scholar
• Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer http://clinicaltrials.gov/ct2/show/NCT01281943
   Google Scholar
• Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients http://clinicaltrials.gov/ct2/show/NCT00999882
   Google Scholar